Literature DB >> 19534837

A history of health technology assessment at the European level.

David Banta1, Finn Børlum Kristensen, Egon Jonsson.   

Abstract

This study summarizes the experience with health technology assessment (HTA) at the European level. Geographically, Europe includes approximately fifty countries with a total of approximately 730 million people. Politically, twenty-seven of these countries (500 million people) have come together in the European Union. The executive branch of the European Union is named the European Commission, which supports several activities, including research, all over Europe and in many other parts of the world. The European Commission has promoted HTA by several policy positions and has funded a series of projects aimed at strengthening HTA in Europe. Around fifteen of the European countries now have formal national programs on HTA and some also have regional public programs. All countries that are members of the European Union and do not have a national approach to HTA have an interest in becoming more involved. The HTA projects sponsored by the European Commission have focused on networking and collaboration among established agencies and institutions for HTA, however, also on capacity building, support, and facilitation in creating mechanisms for HTA in European countries that still do not have any program in the field.

Entities:  

Mesh:

Year:  2009        PMID: 19534837     DOI: 10.1017/S0266462309090448

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  7 in total

1.  HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2020-02

Review 2.  Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

Authors:  Cindy J Nowinski; Deborah M Miller; David Cella
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Debating the desirability of new biomedical technologies: lessons from the introduction of breast cancer screening in the Netherlands.

Authors:  Marianne Boenink
Journal:  Health Care Anal       Date:  2012-03

4.  Evidence-based decision-making for diagnostic and therapeutic methods: the changing landscape of assessment approaches in Germany.

Authors:  Britta Olberg; Sabine Fuchs; Katja Matthias; Alexandra Nolting; Matthias Perleth; Reinhard Busse
Journal:  Health Res Policy Syst       Date:  2017-10-17

5.  HISTORICAL DEVELOPMENT OF THE HTAsiaLINK NETWORK AND ITS KEY DETERMINANTS OF SUCCESS.

Authors:  Yot Teerawattananon; Karlena Luz; Chalarntorn Yothasmutra; Raoh-Fang Pwu; Jeonghoon Ahn; Asrul Akmal Shafie; Kalipso Chalkidou; Sripen Tantivess; Benjarin Santatiwongchai; Waranya Rattanavipapong; Saudamini Dabak
Journal:  Int J Technol Assess Health Care       Date:  2018-06-18       Impact factor: 2.188

6.  Improving Hospital Based Medical Procurement Decisions with Health Technology Assessment and Multi-Criteria Decision Analysis.

Authors:  Chai Yang; Yanjun Wang; Xiaoxuan Hu; Yujun Chen; Liting Qian; Fuchang Li; Wei Gu; Qiang Liu; Di Wang; Xiaoqing Chai
Journal:  Inquiry       Date:  2021 Jan-Dec       Impact factor: 1.730

7.  Development and implementation of health technology assessment: a policy study.

Authors:  Sh Doaee; A Olyaeemanesh; Sh Emami; M Mobinizadeh; P Abooee; M Nejati; Gs Zolani
Journal:  Iran J Public Health       Date:  2013-01-01       Impact factor: 1.429

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.